Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 311
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT00037622 | Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With Chronic Hepatitis B Infection. | ||
| NCT04469465 | Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA) | ||
| NCT05966467 | Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies | ||
| NCT01307098 | Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Participants With Lysosomal Acid Lipase Deficiency | ||
| NCT02345421 | A Study to Identify and Characterize LAL-D Patients in High-risk Populations | ||
| NCT04551586 | A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-In-Capsule in Healthy Adult Participants | ||
| NCT05303324 | Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults | ||
| NCT04940559 | Study of Different Forms of Danicopan (Tablet, Softgel Capsule, Liquid-filled Capsule) in Healthy Participants | ||
| NCT04952545 | Study of ALXN2050 in Healthy Adult Participants of Japanese Descent | ||
| NCT05288829 | A Study of a Single Subcutaneous Dose of ALXN1210 in Healthy Adult Participants | ||
| NCT01194804 | E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients | ||
| NCT03766347 | Pediatric NMOSD Observational Study | ||
| NCT04581785 | Gene Therapy With hLB-001 in Pediatric Patients With Severe Methylmalonic Acidemia | ||
| NCT02949128 | Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) | ||
| NCT05641311 | Pharmacokinetic Study of Oral ALXN1840 in Japanese and Non-Japanese Adult Healthy Participants | ||
| NCT00375609 | Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT) | ||
| NCT03555539 | Study of Danicopan in Participants With Hepatic Impairment | ||
| NCT02372513 | National Lysosomal Acid Lipase Deficiency Study | ||
| NCT05047523 | Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease | ||
| NCT05109390 | A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults | ||
| NCT02090179 | Evaluation of Blood Brain Barrier Integrity and Structural Abnormalities in MPS IIIB Patients Using Multimodal Magnetic Resonance Imaging | ||
| NCT01633489 | Lysosomal Acid Lipase (LAL) Deficiency Registry | ||
| NCT03397888 | The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist | ||
| NCT04233073 | Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery | ||
| NCT06398158 | Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder | ||
| NCT04610580 | Bioavailability Study of 2 Oral Formulations of ALXN1840 | ||
| NCT04623710 | Study of ALXN2050 in Participants With Renal Impairment | ||
| NCT04021082 | CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) | ||
| NCT04195763 | Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa) | ||
| NCT04725812 | Complement Regulation to Undo Systemic Harm in Preeclampsia | ||
| NCT04369469 | Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia | ||
| NCT07557420 | Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD) | ||
| NCT03384186 | A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants | ||
| NCT00751231 | A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI | ||
| NCT02618512 | A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously | ||
| NCT04201262 | An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD | ||
| NCT02329327 | A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study) | ||
| NCT02512562 | A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers | ||
| NCT05202145 | Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants | ||
| NCT01849562 | Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants | ||
| NCT04202341 | Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs) | ||
| NCT00648739 | Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM | ||
| NCT02293408 | Natural History Study to Characterise the Course of Disease Progression in Participants With Mucopolysaccharidosis Type IIIB | ||
| NCT02301624 | Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis | ||
| NCT05288816 | A Study of Single and Multiple Doses of ALXN1210 in Healthy, Adult Japanese Participants | ||
| NCT06173596 | A Study to Evaluate Potential Drug Interactions Between ALXN2080 and Itraconazole, Fluconazole & Carbamazepine in Healthy Adults | ||
| NCT05751642 | Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1920 in Healthy Participants | ||
| NCT01106027 | Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Crossmatch Deceased Donor Kidney Transplant | ||
| NCT01194973 | An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome | ||
| NCT04889677 | Study of a Single Dose of Danicopan in Healthy Participants |
